Unlocking the U.S. hyperbaric market through FDA approval and a scalable, clinic driven growth strategy.
We have successfully designed, engineered, and manufactured a medical grade monoplace hyperbaric oxygen chamber built to meet the demands of global healthcare markets.
Our system is already MDR certified for the European Union, fully compliant under the Medical Device Single Audit Program (MDSAP), and carries the CE Mark, positioning it as a clinically validated, internationally deployable platform.
This significantly de-risks regulatory progression and demonstrates that the device meets stringent international safety and quality standards.
We are now seeking strategic investment to complete the FDA approval process, representing the critical gateway to entering the United States, the world’s largest and most valuable healthcare market. Our regulatory pathway is well-defined, and we are working with an experienced FDA consulting group that is prepared to execute the approval process efficiently and in alignment with U.S. regulatory requirements.
Beyond the device itself, we have developed a fully integrated clinic model, including all operational, clinical, and compliance documentation required to establish and operate medical-grade hyperbaric oxygen therapy (HBOT) clinics. This positions us not only as a device manufacturer, but as a complete program provider, capable of rapidly deploying hyperbaric treatment centers at scale.
Our strategy is to leverage FDA approval to launch a network of HBOT clinics across the United States, targeting high-demand areas such as:
• advanced wound care
• post-radiation injury treatment
• surgical recovery support
• chronic condition management
Significant additional market demand exists in emerging and off-label areas such as stroke recovery, PTSD, traumatic brain injury (TBI), Long COVID, and Lyme disease, further expanding the long-term growth potential of hyperbaric therapy.
This dual approach regulatory approval plus clinic rollout creates a compelling opportunity to generate both device sales revenue and recurring clinical income streams.
We are inviting investors to participate at this pivotal stage, where capital will directly accelerate FDA approval and enable entry into a high-growth U.S. market with a scalable, clinic-based expansion model.
This is an opportunity to support the next phase of growth for a company that has already achieved international certification and is now positioned to unlock significant value through U.S. market entry.
Our CEO has experience in establishing HBOT clinics and overseeing over 2,500 patient treatments in the US and looks forward to answering your questions regarding this opportunity.
We thank you for your interest in our proposal.
Ready to Ask For Funding for your company?
Post a Funding Request